Marine Microorganisms as Sources of Antimalarial Agents

海洋微生物作为抗疟剂的来源

基本信息

批准号：
7329935
负责人：
John Michael Cronan
金额：
$ 26.71万
依托单位：
MAGELLAN BIOSCIENCE GROUP, INC.
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-07-01 至 2008-12-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7329935
关键词：
Adsorption Africa Africa South of the Sahara Age Animals Antimalarials Antiparasitic Agents Antiviral Agents Aotus primate Artemisinins Biological Biological Assay Biological Availability Biological Factors Cessation of life Chemical Structure Chemicals Chemistry Child Chloroquine Class Clinical Collaborations Collection Combined Modality Therapy Communicable Diseases Conditioned Culture Media Country Coupled Development Disease Dose Drug resistance Evaluation Failure Fermentation Florida Foundations Fractionation Funding Genotype Goals Growth Health In Vitro Invertebrates Lead Left Libraries Malaria Mammalian Cell Marines Mediation Medicine Metabolic Modeling Monkeys Morbidity - disease rate Natural Products Chemistry Nature Parasite resistance Parasites Parasitic Diseases Patients Pharmaceutical Preparations Pharmacologic Substance Pharmacology Phase Phenotype Plasmodium falciparum Pregnant Women Preparation Public Health Pyrimethamine-Sulfadoxine Quantitative Structure-Activity Relationship Quinine Rate Recording of previous events Research Research Proposals Resistance Resistance development Resistance profile Resources Rights Screening procedure Small Business Funding Mechanisms Small Business Innovation Research Grant Solubility Source Structure Testing Therapeutic Therapeutic Agents Toxic effect Universities World Health Organization artemisinine base clinically relevant college commercialization cytotoxicity drug discovery experience genotoxicity in vivo man marine natural product microbial microorganism mortality mouse model novel pre-clinical prevent professor programs research study response

项目摘要

DESCRIPTION (provided by applicant): As the search continues for more effective therapeutic agents, marine microorganisms and invertebrates have emerged as a promising new resource yielding unusual chemical structures with potent biological activities. The vast diversity and relatively unexplored nature of these unique sources of chemical diversity suggests they will continue to be an important source of new drugs. The broad goal of this proposal is to discover marine natural product leads from marine microorganisms. SBIR Phase I aim is to identify extracts with potent antimalarial activity from Magellan's library of marine microorganisms. We seek to isolate structures from microorganisms that will be useful against malaria for which there are few effective drug leads. SBIR Phase II aim will be to identify a high quality lead that will progress towards submission of an IND application. We expect to use a combination of natural products chemistry and anti- malaria screens to discover novel chemical compounds useful as anti-malaria agents. This proposal responds to the key national priority to identify new and effective therapeutics against malaria. Malaria is the most important parasitic disease of man and a major cause of morbidity and mortality in tropical and temperate regions worldwide. It is estimated that over 300 million people become infected with malaria each year, with up to 3 million people dying as a result of the disease. The majority of these deaths occur in children under the age of five and pregnant women in sub- Saharan Africa.

描述（由申请人提供）：随着对更有效治疗剂的不断研究，海洋微生物和无脊椎动物已成为一种有前途的新资源，产生具有有效生物活性的不寻常化学结构。这些独特的化学多样性来源的巨大多样性和相对未经探索的性质表明它们将继续成为新药的重要来源。该提案的总体目标是从海洋微生物中发现海洋天然产物。 SBIR 第一阶段的目标是从麦哲伦海洋微生物库中鉴定具有有效抗疟活性的提取物。我们寻求从微生物中分离出可用于对抗疟疾的结构，而疟疾的有效药物很少。 SBIR 第二阶段的目标是确定高质量的先导化合物，以推进 IND 申请的提交。我们期望结合天然产物化学和抗疟疾筛选来发现可用作抗疟疾药物的新型化合物。该提案响应了国家重点优先事项，即寻找新的有效的疟疾疗法。疟疾是人类最重要的寄生虫病，也是全世界热带和温带地区发病和死亡的主要原因。据估计，每年有超过 3 亿人感染疟疾，多达 300 万人因此死亡。其中大部分死亡发生在撒哈拉以南非洲地区的五岁以下儿童和孕妇中。